Om Prakash Dwivedi

Om Prakash Dwivedi

Auto-generated profile, based on publicly available information

Om Prakash Dwivedi

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DADina Mansour Aly
Dina Mansour Aly
ODOm Prakash Dwivedi
Om Prakash Dwivedi
RBRashmi Prasad B
Rashmi Prasad B
AKAnnemari Käräjämäki
Annemari Käräjämäki
RHRebecka Hjort
Rebecka Hjort
EAEmma Ahlqvist
Emma Ahlqvist

1 November 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ODOm Prakash Dwivedi
Om Prakash Dwivedi
MLMikko Lehtovirta
Mikko Lehtovirta
BHBenoit Hastoy
Benoit Hastoy
VCVikash Chandra
Vikash Chandra
NKNicole A. J. Krentz
Nicole A. J. Krentz
LGLeif Groop
Leif Groop

12 March 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
PLPanu Luukkonen
Panu Luukkonen
TTTaru Tukiainen
Taru Tukiainen
AJAnne Juuti
Anne Juuti
HSHenna Sammalkorpi
Henna Sammalkorpi
PHP.A. Nidhina Haridas
P.A. Nidhina Haridas
Hannele Yki-JarvinenHannele Yki-Jarvinen
Hannele Yki-Jarvinen
Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [DNL] and adipose tissue lipolysis [ATL] using 2 H 2 O and 2 H-glycerol) and insulin sensitivity using 3 H-glucose and euglycemic-hyperinsulinemic clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in carriers compared with noncarriers. Expression of 274 genes was altered in carriers compared with noncarriers, consisting predominantly of downregulated inflammation-related gene sets. Plasma IL-6 concentrations were lower, but DNL, ATL and hepatic insulin sensitivity were similar between the groups. In conclusion, carriers of the HSD17B13 variant have decreased fibrosis and expression of inflammation-related genes but increased phospholipids in the liver. These changes are not secondary to steatosis, DNL, ATL, or hepatic insulin sensitivity. The increase in phospholipids and decrease in fibrosis are opposite to features of choline-deficient models of liver disease and suggest HSD17B13 as an attractive therapeutic target.

8 June 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AWAlice Williamson
Alice Williamson
DNDougall M. Norris
Dougall M. Norris
XYXianyong Yin
Xianyong Yin
KBK. Alaine Broadaway
K. Alaine Broadaway
AMAnne H. Moxley
Anne H. Moxley
CLClaudia Langenberg
Claudia Langenberg
Distinct tissue-specific mechanisms mediate insulin action in fasting and postprandial states. Previous genetic studies have largely focused on insulin resistance in the fasting state, where hepatic insulin action dominates. Here we studied genetic variants influencing insulin levels measured 2 h after a glucose challenge in >55,000 participants from three ancestry groups. We identified ten new loci (P < 5 × 10−8) not previously associated with postchallenge insulin resistance, eight of which were shown to share their genetic architecture with type 2 diabetes in colocalization analyses. We investigated candidate genes at a subset of associated loci in cultured cells and identified nine candidate genes newly implicated in the expression or trafficking of GLUT4, the key glucose transporter in postprandial glucose uptake in muscle and fat. By focusing on postprandial insulin resistance, we highlighted the mechanisms of action at type 2 diabetes loci that are not adequately captured by studies of fasting glycemic traits.

26 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
VCVikash Chandra
Vikash Chandra
HIHazem Ibrahim
Hazem Ibrahim
CHClémentine Halliez
Clémentine Halliez
RBRashmi Prasad B
Rashmi Prasad B
FVFederica Vecchio
Federica Vecchio
TOTimo Otonkoski
Timo Otonkoski
Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of insulin producing pancreatic β-cells. One of the genes associated with T1D is TYK2, which encodes a Janus kinase with critical roles in type-Ι interferon (IFN-Ι) mediated intracellular signalling. To study the role of TYK2 in β-cell development and response to IFNα, we generated TYK2 knockout human iPSCs and directed them into the pancreatic endocrine lineage. Here we show that loss of TYK2 compromises the emergence of endocrine precursors by regulating KRAS expression, while mature stem cell-islets (SC-islets) function is not affected. In the SC-islets, the loss or inhibition of TYK2 prevents IFNα-induced antigen processing and presentation, including MHC Class Ι and Class ΙΙ expression, enhancing their survival against CD8+ T-cell cytotoxicity. These results identify an unsuspected role for TYK2 in β-cell development and support TYK2 inhibition in adult β-cells as a potent therapeutic target to halt T1D progression.

19 April 2023 in iScience
Verified
Journal Article
Open access
ODOm Prakash Dwivedi
Om Prakash Dwivedi
KBKarina Barreiro
Karina Barreiro
AKAnnemari Käräjämäki
Annemari Käräjämäki
EVErkka Valo
Erkka Valo
AGAnil K. Giri
Anil K. Giri
MPMaija Puhka
Maija Puhka
Urinary extracellular vesicles (uEV) are a largely unexplored source of kidney-derived mRNAs with potential to serve as a liquid kidney biopsy. We assessed ∼200 uEV mRNA samples from clinical studies by genome-wide sequencing to discover mechanisms and candidate biomarkers of diabetic kidney disease (DKD) in Type 1 diabetes (T1D) with replication in Type 1 and 2 diabetes. Sequencing reproducibly showed >10,000 mRNAs with similarity to kidney transcriptome. T1D DKD groups showed 13 upregulated genes prevalently expressed in proximal tubules, correlated with hyperglycemia and involved in cellular/oxidative stress homeostasis. We used six of them (GPX3, NOX4, MSRB, MSRA, HRSP12, and CRYAB) to construct a transcriptional “stress score” that reflected long-term decline of kidney function and could even identify normoalbuminuric individuals showing early decline. We thus provide workflow and web resource for studying uEV transcriptomes in clinical urine samples and stress-linked DKD markers as potential early non-invasive biomarkers or drug targets.